SYDNEY, Nov. 9, 2022
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX:
KZA), an oncology-focused drug development company, today announced
that final data from its phase II study of paxalisib in patients
with newly diagnosed glioblastoma will be the subject of an oral
presentation at the upcoming annual meeting of the Society for
Neuro-Oncology (SNO), which will be held from 17-20 November in
Tampa, FL.
The oral presentation will build on key findings previously
presented at the ASCO and ESMO annual meetings earlier in the
year.
In addition, Professor Matt Dun
from the Hunter Medical Research Institute at the University of
Newcastle, Australia, will present
the latest data from his ongoing research with paxalisib in diffuse
midline gliomas, an aggressive form of childhood brain cancer.
ORAL PRESENTATIONS
Title:
Multi-center, phase 2 study evaluating the pharmacokinetics, safety
and preliminary efficacy of paxalisib in newly diagnosed adult
patients with unmethylated glioblastoma (GBM).
Date:
Saturday, 19 November
Session:
Clinical Trials: Non-immunologic
Presenter:
Professor Patrick Wen – Dana-Farber
Cancer Institute
Abstract
ID:
CTNI-27
PLENARY PRESENTATION
Title:
Preclinical and case study examination of the combination of the
CLPP agonist ONC201 with the PI3K/AKT inhibitor paxalisib for the
treatment of diffuse midline glioma.
Date:
Friday, 18 November
Session:
Preclinical Experimental Therapeutics
Presenter:
Professor Matt Dun – Hunter Medical
Research Institute
Abstract
ID:
EXTH-12
About Kazia Therapeutics
Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an
oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of
the PI3K / Akt / mTOR pathway, which is being developed to treat
multiple forms of brain cancer. Licensed from Genentech in late
2016, paxalisib is or has been the subject of ten clinical trials
in this disease. A completed phase II study in glioblastoma
reported promising signals of efficacy in 2021, and a pivotal study
for registration, GBM AGILE, is ongoing, with final data expected
in 2H CY2023. Other clinical trials are ongoing in brain
metastases, diffuse midline gliomas, and primary CNS lymphoma, with
several of these having reported encouraging interim data.
Paxalisib was granted Orphan Drug Designation for glioblastoma
by the US FDA in February 2018, and
Fast Track Designation for glioblastoma by the US FDA in
August 2020. In addition, paxalisib
was granted Rare Pediatric Disease Designation and Orphan
Designation by the US FDA for DIPG in August
2020, and for atypical teratoid / rhabdoid tumours (AT/RT)
in June 2022 and July 2022, respectively.
Kazia is also developing EVT801, a small-molecule inhibitor of
VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided
compelling evidence of synergy with immuno-oncology agents. A phase
I study commenced recruitment in November
2021.
For more information, please visit www.kaziatherapeutics.com or
follow us on Twitter @KaziaTx.
This document was authorized for release to the ASX by Dr
James Garner, CEO and Managing
Director.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kazia-to-present-paxalisib-data-in-adult-and-pediatric-brain-cancer-at-society-for-neuro-oncology-annual-meeting-301672518.html
SOURCE Kazia Therapeutics Limited